| Theme | Current Therapy of IBD | |
|---|---|---|
| Title | Recent Developments in Treatment of IBD Using 5-ASA | |
| Publish Date | 2012/01 | |
| Author | Ichiro Hirata | Department of Gastroenterology, Fujita Health University |
| [ Summary ] | 5-ASA formulations for treatment of inflammatory bowel disease (IBD) include SASP, Olsalazine, Balsalazide and Mesalazine (Pentasa®, Asacol®, Salofalk® and Lialda®). SASP is indicated for ulcerative colitis (UC) and Crohnʼs disease (CD) in the large intestine. Pentasa is indicated for CD in the small or large intestine, as well as UC. Indications for its use are wide ranging because this drug is released into the small intestine and migrates to the large intestine. Asacol, a drug released in the ileocecum, is indicated for UC treatment. 5-ASA may be implemented to induce remission in mildto-moderately active UC cases. 5-ASA high dosage therapy and combination therapy with oral 5-ASA for enema are recommended because they are highly effective. A small number of medications achieve adequate compliance. For maintenance therapy, one time administration is recommended. The long-term use of 5-ASA formulations reduces the risk of developing colorectal cancer as well as maintaining remission. The efficacy of 5-ASA formulations for mild to moderate active stage CD is not found in treatments other than SASP. In terms of maintaining remission of CD, neither SASP nor mesalazine are effective. However, both are effective for postoperative maintenance therapy. |
|